NTRK1 and neoplasm: Its anti-tumor effect is mainly competitive with Vascular Endothelial Growth Factor (VEGF) to bind tyrosine kinase receptors, thus reducing angiogenesis—as angiogenesis is necessary for tumor growth [48].